| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 481.85 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Immune checkpoint inhibitors (ICIs) are valuable therapeutic weapons against cancer that potentiate a T cell-mediated immune response. Nivolumab is an ICI that targets the PD-1 receptor. Rheumatic immune-related adverse events (irAEs), which are induced by ICIs, occur in 10% of cases. However, their pathogenesis remains unclear. Synovial biopsy has allowed for a better understanding of the underlying mechanisms of different arthropathies. Key message: Synovial biopsy has a role in understanding the aetiopathogenesis of immune checkpoint inhibitor-induced arthritis.
Description
Keywords
Nivolumab-induced arthritis Synovial biopsy
Pedagogical Context
Citation
Pereira da Costa R, Pinho M, Patrocínio J, Torres S, Ferreira C, Fonseca JE, et al. Synovial biopsy in a case of nivolumab-induced arthritis. Clin Exp Rheumatol. 2025 Sep 2. Epub ahead of print.
Publisher
Clinical and Experimental Rheumatology
